un medicated diagnosed with major depression and scheduled to start SSRI treatment.

Depression

no intervention is being performed, only observational evaluations.

no intervantion

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

david groshar

Assuta Medical Center

patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS

patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo

Multiple System Atrophy

initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose

L-Threo DOPS

initial period (4 weeks) followed by 8 weeks

placebo

Centre hospitalier d'Angers

CHU bordeaux

CHU de Clermont-Ferrand

CHU de Dijon

CHRU de lille

CHU de limoges

Hôpital La Timone

Hôpital G. & R. Laennec

Hôpital Pitié-Salpétrière

CHU de Poitiers

CHU Pontchaillou

CHU de Rouen

chu de Strasbourg

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo

Evaluate the efficacy of long term efficacy of L-threo DOPS (droxidopa) in MSA patients (probable or possible - cerebellar (C) or parkinsonian (P) type) with symptomatic NOH as measured by the relative change in mean score of Orthostatic Hypotension Symptom Assessment (OHSA) (Part I of the questionnaire on the symptoms OH (OHQ) (Kaufmann et al., 2011)) 12 weeks following randomization to therapy with droxidopa or placebo (including 8 weeks to maximum tolerated dose).

Evaluate and compare the efficacy of L-ThreoDOPS on symptomatic OH (measured by the relative change in mean score of Item 1 of the Orthostatic Hypotension Symptom Assessment (OHSA)) in MSA patients 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo

Evaluate the effects of L-Threo DOPS on motor symptoms (UMSARS I and II) in MSA patients after 12 weeks following randomization to continued therapy with droxidopa or placebo

Evaluate the effect of L-Threo DOPS on dysautonomic symptoms (COMPASS) in MSA patients after 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo

Determine the safety of high doses of L-ThreoDOPS in MSA patients based on the occurrence of treatment-emergent adverse events

University Hospital, Toulouse

Fibromyalgia

Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

Droxidopa

Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

Carbidopa

Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.

Droxidopa/carbidopa

Placebo

Rheumatology Department; Barnsley Hospital NHS Foundation Trust

MAC UK Neuroscience

Academic Dept of Rheumatology, Kings College London

Musculoskeletal Department; Freeman Hospital

Rheumatology Department, Poole Hospital NHS Trust

Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia

decarboxylase/fatigue

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası